The Commonwealth Serum Laboratories was established in Australia in 1916.
At CSL, Corporate Responsibility is about conducting our business ethically.
We offer the broadest range of quality plasma-derived and recombinant therapies in the industry.
Seqirus opened in 2015 and is the second largest influenza company in the world.
Innovation has been in the DNA of CSL since our beginning in 1916
Our product portfolio focuses on innovation in new products
Help us deliver on our promise to save lives and protect the health of people.
Diversity and inclusion are top priorities for CSL.
View our ASX announcements
Visit this page to see all of our current news releases
CSL Publishes Vifor Offer Prospectus
CSL Behring AG Publishes Offer Prospectus On Public Tender Offer For All Publicly Held Shares Of Vifor Pharma Ltd.
CSL Committed to mRNA Program
CSL Announces Tender Offer To Acquire Vifor Pharma
CSL Joins StartX Community
Through the StartX partnership, CSL will access an ecosystem of early stage biotech, medtech and digital healthcare ventures,…
Melbourne Biotech Incubator
$2.5 million CSL Centenary Fellowships awarded
CSL Research and Development Day 2021
CSL Committed to AZ COVID Vaccine
CSL Reaffirms Commitment to Manufacture AstraZeneca COVID Vaccine into 2022
CSL Requires COVID-19 Vaccination
CSL Requires COVID-19 Vaccination for On-Site Employees and Visitors
Popular search terms:
Americas
Asia Pacific
Europe
